(Q50652421)
Statements
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. (English)
1 reference
S L Tunis
1 reference
B M Johnstone
1 reference
P J Gibson
1 reference
D L Loosbrock
1 reference
B K Dulisse
1 reference
1 January 1999
1 reference
60 Suppl 19
1 reference
38-45; discussion 46
1 reference